{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:50:48Z","timestamp":1791597048128,"version":"4.3.4"},"reference-count":11,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"abstract":"Abstract<\/jats:title>\n Pretherapeutic dosimetry is an essential component of individualized radioiodine therapy. This study aimed to compare radioiodine therapies planned according to the Marinelli equation or DIN 6861-1:2021-11 with regard to the deviation of the planned and achieved thyroid doses in patients with benign thyroid diseases.<\/jats:p>\n The relative deviation of the achieved thyroid dose during radioiodine therapy from the pretherapeutically planned dose was analyzed according to the applied dosimetric method. Patient cohorts with goiter, recurrent goiter, disseminated and focal thyroid autonomy and autoimmune thyroid disease were evaluated. The cohorts were compared using the Mann\u2013Whitney U- test.<\/jats:p>\n For goiter, recurrent goiter, disseminated thyroid autonomy and focal thyroid autonomy, radioiodine therapies planned according to DIN 6861-1:2021-11 were associated with significantly smaller deviations between the planned and achieved thyroid doses than therapies planned according to the Marinelli equation. Depending on the diagnostic group, the mean relative deviation was approximately 15 to 32 percentage points lower in the DIN cohorts. The DIN cohorts also showed less variability in dose deviations. In patients with autoimmune thyroid disease, no statistically significant differences of the mean relative deviation were observed between the dosimetric methods. However, variability was also lower in the DIN cohorts.<\/jats:p>\n The use of DIN 6861-1:2021-11 is associated with improved prediction of the thyroid dose compared with the Marinelli equation and may contribute to more precise individualized planning of radioiodine therapy in patients with benign thyroid diseases.<\/jats:p>","DOI":"10.1055\/a-2960-8295","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:07:51Z","timestamp":1791241671000},"source":"Crossref","is-referenced-by-count":0,"title":["Marinelli Equation vs. DIN 6861-1: Comparison of the Achieved Therapeutic Thyroid Dose after Radioiodine Therapy Using Different Pretherapeutic Dosimetry"],"prefix":"10.1055","clinical-trial-number":[{"clinical-trial-number":"drks00041071","registry":"10.18810\/drks"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2675-9107","authenticated-orcid":false,"given":"Patrick","family":"Heilfort","sequence":"additional","affiliation":[{"name":"Medical University of Lausitz \u2013 Carl Thiem, BB, Germany","place":["Cottbus"],"department":["Clinic for Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4197-1294","authenticated-orcid":false,"given":"Olga","family":"Varlamova","sequence":"additional","affiliation":[{"name":"Medical University of Lausitz \u2013 Carl Thiem, BB, Germany","place":["Cottbus"],"department":["Clinic for Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kranick","sequence":"additional","affiliation":[{"name":"Medical University of Lausitz \u2013 Carl Thiem, BB, Germany","place":["Cottbus"],"department":["Clinic for Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bredow","sequence":"additional","affiliation":[{"name":"Medical University of Lausitz \u2013 Carl Thiem, BB, Germany","place":["Cottbus"],"department":["Clinic for Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Starke","sequence":"additional","affiliation":[{"name":"Medical University of Lausitz \u2013 Carl Thiem, BB, Germany","place":["Cottbus"],"department":["Clinic for Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1007\/s00259-023-06274-5","article-title":"The EANM guideline on radioiodine therapy of benign thyroid disease","volume":"50","author":"A Campenn\u00ec","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"634955","DOI":"10.3389\/fendo.2021.634955","article-title":"Improved patient dosimetry at radioiodine therapy by combining the ICRP compartment model and the EANM pre-therapeutic standard procedure for benign thyroid diseases","volume":"12","author":"M Andersson","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40658-018-0231-x","article-title":"Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases","volume":"5","author":"J Hammes","year":"2018","journal-title":"EJNMMI Phys"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1055\/s-2008-1076848","article-title":"Dosimetrie bei radioiodtherapie benigner schilddr\u00fcsenerkrankungen \u2013 hintergrund und durchf\u00fchrung","volume":"31","author":"A Bockisch","year":"2008","journal-title":"Der Nuklearmediziner"},{"issue":"02","key":"ref12","first-page":"260","article-title":"Dosage determination with radioactive isotopes; practical considerations in therapy and protection","volume":"59","author":"L D Marinelli","year":"1948","journal-title":"Am J Roentgenol Radium Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1055\/a-1868-5116","article-title":"Statuserfassung des Radiojodtests im klinischen Alltag in Deutschland 2021","volume":"61","author":"P Taghavi","year":"2022","journal-title":"Nuklearmedizin"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MNM.0b013e328333d303","article-title":"Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?","volume":"31","author":"C Kobe","year":"2010","journal-title":"Nucl Med Commun"},{"issue":"04","key":"ref15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.zemedi.2011.01.006","article-title":"Dosimetry prior to I-131-therapy of benign thyroid disease","volume":"21","author":"H H\u00e4nscheid","year":"2011","journal-title":"Z Med Phys"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s00259-013-2387-x","article-title":"EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases","volume":"40","author":"H H\u00e4nscheid","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"03","key":"ref17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/wjnm.WJNM_47_20","article-title":"Determination of administered activities for the treatment of Graves\u2019 disease with iodine-131: proposition of a simplified dosimetric procedure","volume":"20","author":"I A Soli","year":"2021","journal-title":"World J Nucl Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3413\/Nukmed-0875-17-01","article-title":"Radioiodine therapy of benign thyroid-disorders: assessment of the effective half-lives and determination of influence factors within a Southwestern German cohort","volume":"56","author":"T Hartmann","year":"2018","journal-title":"Nuklearmedizin."}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2960-8295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:23:21Z","timestamp":1791595401000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2960-8295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":11,"URL":"https:\/\/doi.org\/10.1055\/a-2960-8295","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}